Ever since Novo Nordisk published data showing significant weight loss effects, there has been a surge in demand for so-called GLP-1 receptor agonists, a class of drugs used to treat type 2 diabetes and obesity, leading to shortages since 2022.
While manufacturing constraints are part of…
[ad_2]
Source link
